Meeting
2018 Gastrointestinal Cancers Symposium
Efficacy of oral chemotherapy with capecitabine and temozolomide (CapTem) in metastatic neuroendocrine tumors (NETs): A single-institution experience.
Authors
Valeria Smiroldo
Humanitas Research Hospital-IRCCS, Rozzano (Milan), Italy
Valeria Smiroldo , Carlo Carnaghi , Lorenza Rimassa , Nicola Personeni , Tiziana Pressiani , Silvia Bozzarelli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 487)
DOI
10.1200/JCO.2018.36.4_suppl.487
Abstract #
487
Poster Bd #
N11
Abstract Disclosures
Similar Posters
Poster
2014 Gastrointestinal Cancers Symposium
Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors.
First Author: Robert Lance Fine
Poster
2013 Gastrointestinal Cancers Symposium
The efficacy and safety of the capecitabine/temozolomide (CAPTEM) regimen in the treatment of well-differentiated neuroendocrine tumors with liver metastasis after failure of previous therapy: Columbia University Medical Center experience.
First Author: Paul Oberstein
First Author: Evan Justin Walker
Poster
2021 Gastrointestinal Cancers Symposium
Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms.
First Author: Taymeyah E. Al-Toubah